CELL: Chinese researchers have developed a new crown candidate vaccine, and can be mass-produced
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The 2019 coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), is in the midst of a pandemic and threatens global public healthThe prevention and control of COVID-19 is in urgent need of vaccine developmentHere, researchers from several research institutions in China reported the experimental scale production of an inactivated SARS-CoV-2 vaccine candidate vaccine (BBIBP-CorV)The vaccine induces mice, rats, guinea pigs, rabbits and non-human primates (canine and macaques) to produce high levels of neutralizing antibody titer to provide protection against SARS-CoV-2two doses of immunity using 2 micrograms/dose of BBIBP-CorV, which can efficiently protect macaques from SARS-CoV-2's trachea challenges without detecting an antibody-dependent infection enhancementin addition, BBIBP-CorV demonstrates efficient productivity and good genetic stability and can be used in vaccine productionThese results support further evaluation of BBIBP-CorV in clinical trials
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
